OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential	372
Network pharmacology: curing causal mechanisms instead of treating symptoms	295
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic	275
Organ-on-a-Chip: A New Paradigm for Drug Development	231
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19	212
NLRP3 and pyroptosis blockers for treating inflammatory diseases	200
Causes and Consequences of Snake Venom Variation	187
Can Activation of NRF2 Be a Strategy against COVID-19?	156
In Vitro and Animal Models for SARS-CoV-2 research	149
A Perspective on Multi-target Drugs for Alzheimer’s Disease	147
Paving the Road for RNA Therapeutics	143
Tryptophan Metabolism as a Pharmacological Target	136
Emerging New Concepts of Degrader Technologies	116
Drug Repurposing for Rare Diseases	105
Metformin and Systemic Metabolism	105
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	100
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	93
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	93
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	89
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	86
Iron metabolism: pathophysiology and pharmacology	85
Physiological and pharmacological modulation of BAX	84
Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration	80
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	78
Update and latest advances in antiretroviral therapy	72

Targeting the Immune System for Ischemic Stroke	72
Progranulin as a therapeutic target in neurodegenerative diseases	70
AKAP Signaling Islands: Venues for Precision Pharmacology	70
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades	69
Nrf2 for cardiac protection: pharmacological options against oxidative stress	65
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	64
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance	61
Tackling TAMs for Cancer Immunotherapy: It’s Nano Time	60
Recent breakthroughs and future directions in drugging aquaporins	60
Disrupting 3D printing of medicines with machine learning	59
Inhaled RNA Therapy: From Promise to Reality	57
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality	56
Deciphering the TCR Repertoire to Solve the COVID-19 Mystery	55
Advances and challenges in therapeutic targeting of NRF2	54
Charting the Fragmented Landscape of Drug Synergy	53
Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy	50
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	48
Circulating tumor cells in precision medicine: challenges and opportunities	48
Polyunsaturated Fatty Acid Deuteration against Neurodegeneration	46
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	46
Carbon Monoxide: from Poison to Clinical Trials	46